Elevation Oncology, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Elevation Oncology's 10-K filing summarizes the company's financial performance in 2024 and provides updates on its clinical development programs, including EO-3021 and EO-1022.
Elevation Oncology is advancing its lead drug candidate, EO-3021, through clinical trials while also developing a HER3-targeting ADC program.